28.3 C
Vientiane
Sunday, July 20, 2025
spot_img
Home Blog Page 2985

Breakthroughs International Conference Malaysia 2021 gathers kinesiology practitioners online globally for the first time ever

KUALA LUMPUR, MALAYSIA – Media OutReach – 30 June 2021 – Breakthroughs International Conference Malaysia 2021 (BTiC 2021) is set to bring together experts, consultants and learners alike in the field of kinesiology for its first-ever global online conference. Taking place from 29 July to 1 Aug 2021, BTiC 2021 will feature some 30 leading expert practitioners of various movement methodologies for optimal neurological development and physical wellbeing.

Hosted by Malaysia Brain Gym® Association, BTiC 2021 features dozens of related topics such as The Crispiani Method, Classical Movement, Balanced Diet, Neurobiological Foundation, Co-regulation and many others. These will be especially beneficial to Brain Gym® and MBL professionals, educationists and parents of school-age children, including those who have special needs.

Conference Keynote Speakers include:

  • Dr Paul and Gail Dennison, Brain Gym® and Educational Kinesiology Developers, USA, presenting on Brain Gym® Games for Kids of All Ages,
  • Prof Piero Crispiani and Dr Eleonora Palmieri, Italy, co-presenting on Cognitive Motor Training (CMT) and Champion Pressing Practices for Neuro-activation,
  • Kim Barthel, Occupational Therapist, Canada, presenting on Movement and Play as Neurobiological Foundation,
  • Ron Jones, Historical Kinesiologist and Physical & Health Educator, USA, presenting on exercise as the key to good physical and emotional health,
  • Dr Ng Meng Lek, Educational Psychologist and Founder of NeuroLAT, Singapore, presenting on how to Diagnose Your Child’s Ability
  • Viv Hailwood, Founder of Brainchild Development Programme, UK, presenting on the inequality of research resources on future impact of school and employment,
  • Amy Choi, Co-founder of Brain Body Centre, Hong Kong, presenting on how to Trust Your Intuition,
  • Dr Tan Shot Yen, Medical Doctor and PhD in Nutrition, Indonesia, presenting on Balanced Diet in Improving Immunity,
  • Phoebe Long and Minaz Ajani, International Faculty of Breakthroughs International, Malaysia and India, co-presenting on A Brake to Break Vicious Cycles of Stressful Reaction with Co-regulation, and
  • Many more international experts in kinesiology.

Over four days, participants will be able to participate in real-time talks, pre-recorded presentations and live Q&A sessions with the keynote speakers and presenters. Participants will also enjoy unlimited replay for 30 days after. In addition, Brain Gym® instructors will receive 32 CEU hours for re-licensure.

Professionals and parents interested in kinesiology, Brain Gym®, MBL and other modalities are urged to visit the following website to sign up before spaces run out: https://btic2021.online/ (and save $30 USD using promo code: COV19).

About Breakthroughs International Conference

Breakthroughs International Conference had its start in 1988 as Brain Gym® Gatherings in the US.


The first international Conference was convened in Toronto, Canada in 1998. Since then, the conference has made its way around the globe, alternating between cities in the US and internationally.

BTiC 2021 will be the first time the Conference is hosted by Malaysia, as well as the first that will be held virtually, further lowering the barrier to entry for participants from all over the world.

More info: https://btic2021.online/

#BreakthroughsInternationalConference

About Malaysia Brain Gym® Association

Malaysia Brain Gym® Association (MBGA) is committed to the principle that moving with intention leads to optimal learning.


Founded in 2018 and representing more than 70 Brain Gym® instructors, consultants, facilitators and students, MBGA is the premier body working to elevate the knowledge and practice of kinesiology among its members, Malaysian society at large, and beyond.

More info: https://www.braingym.my/

#MalaysiaBrainGymAssociation

Callsign Warns That More Than Half of Consumers Trust Organizations Less After Receiving Scam Messages From Fraudsters Impersonating Their Brand Name

Consumers receive 3 scams a day, with a quarter receiving more messages from fraudsters than genuine messages from friends and family.

HONG KONG SAR – Media OutReach – 30 June 2021 – Callsign, the digital identity pioneer, revealed today that the rise of scams is harming organizations’ reputations across the world. The global study* of consumers revealed that just receiving a scam message purporting to be from any brand is enough for 52% of them to lose trust in the organization regardless of any real association with the message.

Industries most targeted by fraudsters are financial services and public sector organizations with consumers stating that of all scam messages they receive, 60% claim to represent their bank, or a public sector provider (40%).

The scam problem is rampant across all communications channels. Globally, on average, individuals who receive scam messages via all channels receive 1133 a year, with more than a quarter 28% saying they receive more messages from fraudsters than friends and family.

With 52% of consumers admitting they don’t report fraudulent messages, the scale of scam messaging and victims is likely to be underestimated.

“Fraud hides in volume and the rapid migration of the global population online in the last 18 months has led to the industrialization of scams. The consequence is fraudsters are using the same channels we’re using to authenticate genuine consumers, and this is harming organizations’ reputations with the decrease of trust in their brands,” explained Stuart Dobbie, Senior Vice President, Innovation, Callsign.

The survey is a reminder that consumers have a choice. Almost a third (29%) of consumers who have been a victim of fraud say they have stopped using the company whose name the fraudster used to execute the scam. In comparison consumers are less likely to leave the channel the scam is executed through (only 13% would leave their network provider) demonstrating that regardless of the scam method, it’s the brand being mimicked that suffers.

SMS appears to be the weakest link with only 8% of consumers thinking it is a safe channel to communicate with their bank or retailer, and the channel has seen a 57% decrease in trust from those surveyed just because they have received a scam text message.

“Organizations need to re-evaluate the communications channels they use to interact with customers to better establish trust. With fraudsters monopolizing open channels such as SMS and email, these channels cannot be relied upon to also authenticate identity. Our research shows that almost half (45%) of consumers think identity is the problem and that people should prove who they are when signing up to use a platform to stop scammers. These consumer concerns emphasize organizations must wake up to the importance of digital identification,” explained Dobbie.

Dobbie concluded: “If organizations are to maintain and build trust in the digital world, they need to better balance protection and experience to ensure their brand is not tarnished by scammers. With Intelligence Driven Authentication, organizations can overcome the fraudsters, protect their brand, create seamless and secure customer journeys and build all important digital trust.”

Editors notes.

*All figures, unless stated are from Opinium. The total sample size was 9,568 adults with the following national breakdown: Brazil, 1000; Germany, 1000; Hong Kong, 420; India, 553; Indonesia, 541; Philippines, 529; Singapore, 457; UK 1000; USA, 2003.

Regional samples; Benelux, 500; Middle East and Africa (United Arab Emirates, Kingdom of Saudi Arabia, Qatar, Bahrain, South Africa) 1065; Nordics; 500. The fieldwork was carried out online by Opinium in June 2021.

About Callsign

Callsign is pioneering the global network for identification. We solve challenges that organizations face in getting their users on to and interacting with their digital platforms easily and securely. We provide solutions to some of the world’s largest banks and offer “bank-grade” identification to public and private sector clients of all sizes. Callsign’s Intelligence Driven Authentication recognizes users by combining deep learning insights with personalized and contextual customer journeys. As a result, users can get on with their digital lives whilst businesses improve customer engagement, increase productivity and reduce the risk of fraud.

To learn more about Callsign and how it is helping businesses to intelligently protect against global threats in real-time visit: https://www.callsign.com/

#Callsign

Laos Joins Monthly Railway Meetings with Thailand and China.

Laos joins railway monthly meeting between Thailand and China
A high-speed train in China (Photo: 终有 那天).

Laos is to join a monthly meeting previously held between Thailand and China that will review updates on the progress of a plan to connect the Thai-Chinese high-speed rail system in Thailand with Laos.

Jacobson Pharma Announces FY2021 Annual Results

Declares Final Dividend of HK1.5 Cents Per Share; Resilient Performance Albeit Market Challenges

HONG KONG SAR – Media OutReach – 29 June 2021 – Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the “Group”) for the year ended 31 March 2021 (the “FY2021” or the “Reporting Period”).

During the Reporting Period, the economy was hit hard by the pandemic with retail consumption stalled due to various social distancing measures and travel restrictions. At the continual impact of the pandemic on its businesses, the Group made total revenue of HK$1,445.9 million in the Reporting Period, dropped narrowly by 8.0% against the previous year. Mitigated by the impact relief and cost-saving measures, profit attributable to shareholders softened by 19.4% to HK$173.7 million.

The Board has recommended payment of a final dividend of HK1.5 cents per share (FY2020: HK2.5 cents per share). Including the interim dividend of HK0.8 cent per share already paid and a special interim dividend made by the Company on 5 February 2021 in the form of distribution in specie based on 1 share in JBM (Healthcare) Limited (“JBM Healthcare”; Stock Code: 2161) at HK$1.20 per share for every 8 shares held by the shareholders of the Company which represented a distribution of approximately HK15 cents per share, the total dividend for FY2021 would be HK17.3 cents per share (FY2020 total dividend: HK4.5 cents per share).

Steady Growth of Generic Drugs Business in Public Sector

The generic drugs business of the Group recorded revenue of HK$1,048.8 million in the Reporting Period, with the public sector business reporting steady growth but offset by a drop in sales momentum of the private sector business considerably dampened by infection control measures under the pandemic.

The Group’s offerings in certain therapeutic classes saw solid growth, with oral anti-diabetics and gastrointestinal product classes registering a growth of 28.3% and 26.0% respectively in the public sector, mainly attributable to the realisation of tendering business plus increased usage of these essential medicines in respective disease management. In addition, the Group’s angiotensin-converting enzyme inhibitor class and angiotensin II antagonist class of cardiovascular products achieved robust sales growth of 62.2% and 33.6% respectively, alongside an increase in the public sector consumption of antihypertensive drugs.

In the Reporting Period, the Group launched a number of new products including Arsenic Trioxide Oral Solution, Dihydrocodeine Tablet, Perindopril Tablet, Atomoxetine Capsule, Rosuvastatin Tablet, and Hydroxychloroquine Tablet. Among these, Arsenic Trioxide Oral Solution is the first ever Arsenic Trioxide approved in Hong Kong for the treatment of Acute Promyelocytic Leukaemia.

The Group also signed in-license regional agreements with reputable manufacturers in Europe and South Korea for a total of 15 specialised drugs covering the central nervous system, infectious diseases, gastrointestinal, and other therapeutic classes.

Resilient Performance of Branded Healthcare Business

The branded healthcare business of the Group recorded revenue of HK$397.1 million during the Reporting Period, up by 4.1% year-on-year. The growth was mainly attributable to the robust sales of Hoitin (海天) in concentrated Chinese medicine granules products of the Orizen Group, coupled with the resilient performance of AIM Atropine Eye Drops and Flying Eagle Woodlok Oil albeit market challenges.

Distribution of Fosun BioNTech Comirnaty Vaccine in Hong Kong and Macau

The Group is the distributor of Fosun Pharma/BioNTech Comirnaty COVID-19 mRNA Vaccine (“Fosun BioNTech Comirnaty Vaccine”) in Hong Kong and Macau under an exclusive distribution agreement with Fosun Pharma Group. The Fosun BioNTech Comirnaty vaccination programme started in Hong Kong on 10 March 2021, and as at 31 May 2021, over 1.3 million doses of the vaccine have been administered.

Fosun BioNTech Comirnaty Vaccine is an mRNA based vaccine developed by German biotech company BioNTech SE with a clinically-tested efficacy rate of 95%. The Advisory Committee of the United States Centers for Disease Control and Prevention (CDC) has recently endorsed the safety and effectiveness of the vaccine and its use in 12-through 15-year-old adolescents, which represented important progress on COVID-19 infection control within the population.

Successful Spin-off of JBM Healthcare

The Group successfully spun off and separately listed its branded healthcare business, JBM Healthcare, on the Main Board of the Stock Exchange on 5 February 2021. After the spin-off and public listing, the Group holds 53.74% stake in JBM Healthcare in effect, which remains as a subsidiary of the Group.

JBM Healthcare is a Hong Kong-based branded healthcare company with a product footprint covering Greater China, Southeast Asia and other selected countries. It principally engages in the manufacturing and trading of branded healthcare products, comprising consumer healthcare products and proprietary Chinese medicines. The spin-off will create two distinct platforms for the Group and JBM Healthcare to enhance their strategic focuses and sharpen the execution of their growth strategies respectively.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, concluded, “Although market situations have been challenging, the Group has remained steadfast in delivering its growth strategies and fortifying its leadership in the generic drugs market in Hong Kong. In our collaborative fight against the pandemic, Jacobson took pride in playing a part in introducing the Fosun BioNTech Comirnaty Vaccine into the markets of Hong Kong and Macau. I am particularly thankful for the dedicated efforts of our professional pharmacist teams who worked diligently with our business partners in setting up the systems on regulatory compliance, pharmacovigilance and medical information dissemination for seamless execution of the vaccination program.”

“Looking ahead, with proven technological know-how, commercial strengths and priding operational excellence, the Group remains confident in delivering sustainable growth and creating values to our shareholders in the long term.”

About Jacobson Pharma Corporation Limited (雅各臣科研製藥有限公司;Stock Code: 2633)

Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated with the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public market sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.

The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group’s website: http://www.jacobsonpharma.com

#JacobsonPharma

JBM Healthcare Announces FY2021 Annual Results

Adjusted Net Profit* Increases by 13.3% to HK$54.6 Million

HONG KONG SAR – Media OutReach – 29 June 2021 – JBM (Healthcare) Limited (“JBM Healthcare” or the “Group”; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the first annual results of the Group after its spin-off listing on the Main Board of The Stock Exchange of Hong Kong Limited on 5 February 2021.

Despite the unprecedented challenges due to the COVID-19 pandemic, the Group posted a total revenue of HK$397.2 million during the year ended 31 March 2021 (“Reporting Period”), representing a growth of 4.1% from last year. Before taking into account the one-off listing expenses, the adjusted net profit* increased by 13.3% to HK$54.6 million when compared with last year. Basic earnings per share was HK2.78 cents.

Resilient Performance Driven by Strong Product Portfolio

JBM Healthcare carries a robust and broad portfolio of branded healthcare products in the segments of branded medicines, proprietary Chinese medicines, and health and wellness products.

As for the proprietary Chinese medicines (“PCM“) business, sales revenue notably increased by 14.6% to HK$210.9 million, driven by the buoyant performance of Hoitin (海天) concentrated Chinese medicine granules products, alongside a 16.8% revenue growth on Flying Eagle Woodlok Oil (飛鷹活絡油) attributed to a broadened sales penetration in China.

During the Reporting Period, the Group has enriched its PCM product portfolio to include third-party brands, namely Angong Niuhuang Wan (安宮牛黃丸) and Ganoderma Spores (靈芝胞子), to exploit the potential demand of the Chinese market.

The branded medicines business of the Group recorded revenue of HK$134.5 million during the Reporting Period, representing a drop of 5.4% from last year. Among its well-established brands, sales of AIM Atropine Eye Drops delivered year-on-year growth of 9.7% despite the disruption by the COVID-19 pandemic on the consultation visits of children to hospitals and ophthalmologists.

For health and wellness products, sales revenue recorded a moderate decline of 6.3% during the Reporting Period under the impact of the COVID-19 outbreak. This product segment comprises supplements, personal care products, as well as diagnostic for the general health and wellness of consumers. Among these, the demand for personal hygiene and infection control products within the segment surged. As part of its strategy to further enhance its health and wellness product offerings, the Group launched the Dr. Freeman® product series, a health and wellness product line, in response to the growing market demand for infection control and personal hygiene products.

Establishment of Flagship Online Stores

To tap the potential of fast-growing PRC cross-border e-commerce, the Group has established self-operated flagship online stores on Tmall Global Marketplace (天貓賣場型旗艦店) and JD-HK Open Platform (京東國際開放平台店舖) with an expanded selection of more than 40 branded quality healthcare products for Chinese consumers. JBM Healthcare has set up its own e-commerce team in Shenzhen, the PRC, providing direct operational and customer service support for its online flagship stores.

Formation of a Joint Venture with Tycoon Group

The Group has entered into collaboration agreements with Tycoon Group Holdings Limited (“Tycoon Group”; Stock Code: 3390) in a bid to leverage synergies in the market segments of PCM, Chinese healthcare and supplement products. Through this strategic co-operation, the Group is to develop and/or manufacture own-brand products to cater to market trends and consumer needs via a joint venture company newly-formed by the parties to provide distribution, strategic marketing and sales support for these products. The own-brand products are expected to be launched in the third quarter of 2021.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, said, “2020 has set off with a rough ride. Against the backdrop of the pandemic, we remained steadfast with our resolve to navigate the impact of COVID-19 on our business. Thanks to the robust commitment of our team in delivering the strategies, along with our diversified portfolio of offerings and geographic markets, we managed to sustain a resilient performance albeit the market challenges. Moving forward, we will continue to strengthen our commercial capabilities both offline and online, enrich our portfolio targeting unmet healthcare needs, expand our core market coverage in Greater China and Asia, and fortify our collaboration with strategic partners – to strengthen our position as a key provider of healthcare solutions in the region.”

About JBM (Healthcare) Limited (健倍苗苗(保健)有限公司;Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritizes product efficacy and quality to meet consumers’ healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognized household brands such as Po Chai Pills (保濟丸), Ho Chai Kung Tji Thung San (何濟公止痛退熱散), Contractubex (德國秀碧除疤膏), Bite-X (德國寶寶手指水), Mederma Kids (美德瑪寶兒除疤膏), Tong Tai Chung Woodlok Oil (唐太宗活絡油), Flying Eagle Woodlok Oil (飛鷹活絡油), Saplingtan (十靈丹) and Shiling Oil (十靈油). For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk

#JBMHealthcare

Cushman & Wakefield Takes Home Top Honors Across Multiple Service Lines at the RICS Awards China 2021

HONG KONG SAR – Media OutReach – 29 June 2021 – Global real estate services firm Cushman & Wakefield has again been recognized for its leading service excellence and industry achievements at the Royal Institution of Chartered Surveyors (RICS) Awards in China. The firm took home a number of top honors.

K K Chiu, Chief Executive, Greater China, Cushman & Wakefield said, “Congratulations to our expert teams on their outstanding performance. This recognition at the RICS Awards China reflects our company’s steadfast commitment to client-centric service and industry innovation. Although 2021 is still a year with incredible challenges, we have together proven our resilience while elevating Cushman & Wakefield’s brand and leadership position in the industry to a new level. We will continue to maintain our momentum to deliver unmatched professional services and to lead the development of the CRE industry in China.”

Four Winners

  • Professional Consultancy Service Team of the Year – Real Estate (Valuation & Advisory Services Team, Cushman & Wakefield)
  • Research Team of the Year (Research Team, Cushman & Wakefield)
  • Best Deal of the Year (Suntec Place Sanlin, formerly Shanghai Sanlin InCity, Capital Markets, Cushman & Wakefield)
  • Real Estate Financing Innovation Achievement of the Year (Cainiao Logistics Infrastructure Quasi-REITs, a joint collaboration by Cainiao, the Valuation & Advisory Services team of Cushman & Wakefield, GSUM Fund Management and CITIC Securities)


Seven Certificates of Excellence

  • Professional Consultancy Service Team of the Year – Real Estate (Consulting Team, Cushman & Wakefield)
  • Commercial Project of the Year (Shanghai FTZ International Artwork Exchange Center (SFIAE), Project & Development Services, Cushman & Wakefield)
  • Commercial Project of the Year (Columbia Circle Consultancy Services, Project & Occupier Services/Retail Services, Cushman & Wakefield)
  • Regeneration Project of the Year (Planning of Downtown-Life-Circle Revitalization Around Chengdu 1st Ring Road, Consulting, Cushman & Wakefield)
  • Best Deal of the Year (Beijing Indo Mansion Tower D, Capital Markets, Cushman & Wakefield)
  • Sustainability Achievement of the Year (1788 SQUARE, Project & Development Services, Cushman & Wakefield)
  • Real Estate Financing Innovation Achievement of the Year (Joint Venture Cooperative Project in Mawan District of the Qianhai Free Trade Zone, Valuation & Advisory Services, Cushman & Wakefield)

Three Finalists Awards

  • Regeneration Project of the Year (Qingdao International Cruise Terminal Urban Renewal, Consulting, Cushman & Wakefield)
  • Regeneration Project of the Year (Guangzhou Julong Bay Urban Regeneration and Industry Planning, Consulting, Cushman & Wakefield)
  • Best Deal of the Year (Shanghai Fuyuan Landmark Plaza, Building 1, Capital Markets, Cushman & Wakefield)

About RICS China Awards

RICS Awards enjoys a high reputation in the global real estate and construction industries with over 20 years of history, aimed at rewarding excellent achievements by outstanding teams or projects, and their contributions to the built environment. Since its inception in China, the awards have successfully showcased the most inspirational initiatives and achievements in local land, real estate, construction and infrastructure development. The award series is widely recognized within the industry, with each category designed to showcase expert achievements and influence.

Photo download link: https://bit.ly/3qxTzGd

#RICSChinaAwards

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 50,000 employees in over 400 offices and 60 countries. Across Greater China, 22 offices are servicing the local market. The company won four of the top awards in the Euromoney Survey 2017, 2018 and 2020 in the categories of Overall, Agency Letting/Sales, Valuation and Research in China. In 2020, the firm had revenue of $7.8 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services. To learn more, visit www.cushmanwakefield.com.hk or follow us on LinkedIn (https://www.linkedin.com/company/cushman-&-wakefield-greater-china).

#Cushman&Wakefield

Phonhong District Enters Lockdown to Curb Spread of Covid-19

Phonhong goes into lockdown

Phonhong District in Vientiane Province is being placed under lockdown following an outbreak of Covid-19 in the district.

EDL Issues Statement on LAK 68 Million Electricity Bill

Electricity du Laos Makes Live Statement on High Electricity Bill
Électricité du Laos makes a live statement on a resident's high electricity bill.

Electricite du Laos has made a statement after issuing a LAK 68 million electricity bill to a resident of Vientiane Capital.